Form 4/A for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-01-16 00:00:00 ET · period of report 2025-11-28 · accession 0001643653-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2026-01-16 | 2025-11-28 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $35.99 | +12.8K | 57.7K | +29% | +$461.8K |
| DA | 2026-01-16 | 2025-11-28 | NBIX | BENEVICH ERIC | Chief Commercial Off | M - OptEx | $0.00 | -12.8K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-28 | M | A | 12,830 | $35.99 | 57,723 | D | — | — | (F2) Includes an aggregate of 204 shares purchased on February 28, 2025 and August 29, 2025 from the Neurocrine Biosciences, Inc. 2018 Employee Stock Purchase Plan. |
| 2 | Derivative | Incentive Stock Option | 2025-11-28 | M | D | 12,830 | $0.00 | 0 | D | $35.99 · — to 2026-02-05 | 12,830 Common Stock | (F4) The option was granted February 5, 2016 and vested in 48 equal monthly installments beginning March 5, 2016. These options were due to expire on February 5, 2026. |